MedioGen, a domestic probiotics research corporation, announced on the 24th that it has entered into a strategic partnership with Maypharm Life Sciences Pvt Ltd in India and signed a five-year exclusive distribution agreement for MedioGen's functional diet probiotic 'MED-02' in the Mexican and Brazilian markets.
Maypharm Life Sciences is a healthcare corporation in India and a global pharmaceutical distribution company with subsidiaries in São Paulo, Brazil, and Mexico. Through this agreement, the functional diet probiotic MED-02 will be distributed and sold locally in Mexico and Brazil, with a condition guaranteeing a total volume worth 5 billion won during the contract period.
MED-02 is a high-functionality probiotic specialized in body fat reduction and dieting, with its effectiveness in reducing body fat and improving gut health scientifically verified through numerous clinical studies.
Kim Joon-Hwan, the head of MedioGen's strategic planning division, noted, "Following our entry into the Southeast Asian market, we plan to accelerate our entry into the global market through this South American market. Based on our top domestic probiotics research and development capabilities and largest manufacturing facilities, we will continue to expand exports of functional strategy items including diet, women's health, gut health, oral health, and skin health."
Founded in 2000, MedioGen became a subsidiary of Yuhan Corporation in 2020 after investments by Yuhan Corporation and GI Innovation, with Yuhan Corporation being the largest shareholder. Hong Joon-Ho of GI Innovation is also acting in a dual capacity. MedioGen is producing Yuhan Corporation's WiseBiome Family Series and GI Innovation's Number 7.